# US 2018/0021327 A1 · Treatment of corneal neovascularization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021327 A1
- Document ID: US20180021327A1
- Status: Published application
- Kind: A1
- Application number: 15/672,982
- Filed: 2017-08-09
- Published: 2018-01-25
- Earliest claimed: 2011-07-04
- Assignees: Irbm - Science Park S.P.A.
- Applicants: IRBM SCIENCE PARK S.p.A.
- Inventors: Giulio FERRARI
- Web page: https://patentgrep.com/patent/US20180021327A1

## CPC

- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.

## Claims

### Claim 1

A method of preventing corneal neovascularization (“CNV”) which comprises administering to a subject in need thereof a therapeutically effective amount of an NK-1 antagonist selected from the group consisting of fosaprepitant, aprepitant, lanepitant and befetupitant and pharmaceutically acceptable salts of any one thereof, wherein the NK-1 antagonist is administered topically to the cornea.

### Claim 2 (depends on 1)

The method of claim 1 wherein CNV is concurrent or consequential to an inflammatory condition.

### Claim 3 (depends on 1)

The method of claim 1 wherein CNV is caused by one of the following conditions: bacterial infection, viral infection, Chlamydia trachomatis infection, infectious keratitis including herpes simplex keratitis, viral interstitial keratitis, infections caused by staphylococcus, streptococcus, Pseudomonas or microbial keratoconjunctivitis, Pseudomonas aeruginosa infection, chemical or physical insult of the eye, degenerative and traumatic disorders, dry eye, progressive corneal vascularization caused by graft-versus-host disease, limbal stem cell deficiency (including idiopathic, traumatic, aniridia, autoimmune polyendocrinopathy), Stevens-Johnson syndrome, ocular pemphigoid, recurrent pterygium following surgery, extended wearing of hydrogel contact lenses.

### Claim 4 (depends on 1)

The method of claim 1 wherein the NK-1 antagonist is aprepitant or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method of claim 1 wherein the NK-1 antagonist is befetupitant or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The method of claim 1 wherein the NK-1 antagonist is lanepitant or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1 wherein the NK-1 antagonist is fosaprepitant or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The method of claim 1 wherein the NK-1 antagonist is administered in combination, by the same or a different route, with one or more further therapeutically active agents.

### Claim 9 (depends on 8)

The method of claim 8 wherein the at least one of the one or more further therapeutically active agents is administered topically to the eye.
